ClinicalTrials.gg
Status unknownNCT05644535Updated Dec 9, 2022

Cerebrospinal Fluid Gravity Correlation Analysis

An observational study in Specific Gravity and Cerebrospinal Fluid, sponsored by First People's Hospital of Chenzhou. Status unknown at 1 site in China. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-09.

Sponsored by First People's Hospital of Chenzhou · Observational

How we know

The sponsor has not verified this record recently (last verified Nov 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
80
Ages
60 Years and older
Sex
All
01

Study summary

The purpose of this study was to measure cerebrospinal fluid density in aged patients and to see if there was a correlation between these factors and cerebrospinal fluid density by using the electronic medical record system to understand the patient's gender, blood glucose, blood biochemical electrolytes and blood levels.

Read the detailed description

Hip joint injury is one of the common injuries in the elderly, and hip arthroplasty is a treatment method that allows patients to get out of bed and return to social life as soon as possible. Currently, the common position for hip arthroplasty is the lateral position; and combined spinal and epidural anesthesia or subarachnoid anesthesia is also the common anesthesia method for hip arthroplasty. In the lateral position, the patient's affected limb is often on top and the healthy limb is on the bottom; the healthy side position is also the usual position for hip arthroplasty. In this position, it may be optimal to use a lighter specific gravity local anesthetic drug because it tends to anesthetize only the upper affected limb and does not require a return to the supine position after anesthesia due to changes in the plane of block, minimizing pain and hemodynamic fluctuations during anesthesia and position changes.

Currently, light specific gravity is more of a concept. Because in the available data, only the range of cerebrospinal fluid density of ordinary healthy adults is available, there is little literature and data to describe and analyze what the cerebrospinal fluid density of elderly patients actually is. Therefore, when we administer subarachnoid anesthesia to elderly patients, we cannot determine whether the dispensed local anesthetic drug is a light specific gravity.

In this study, we intend to collect cerebrospinal fluid from elderly patients who underwent hip arthroplasty under combined lumbar and rigid anesthesia or subarachnoid anesthesia, and measure the cerebrospinal fluid density in elderly patients, and observe whether there is a correlation between the above factors and cerebrospinal fluid density through the electronic medical record system to understand the patient's gender, blood glucose, blood biochemical electrolytes and routine blood levels; thus, we can better guide the use of lighter specific gravity drugs in clinical practice.

02

Conditions studied

  • Specific Gravity
  • Cerebrospinal Fluid

Keywords

  • Cerebrospinal fluid
  • Correlation Analysis
  • Lighter Specific Gravity
03

In context

Lead sponsor

First People's Hospital of Chenzhou is the lead sponsor of 13 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Selected aged patients who had hip arthroplasty in our hospital between December 2022 and May 2023

Inclusion criteria

  • Receiving combined spinal and epidural anesthesia or subarachnoid anesthesia ASA Ⅰ or Ⅱ patients No significant neurological pathology No recent history of cerebral infarction No recent history of cerebral hemorrhage No central nervous system inflammation No spinal inflammatory disease No history of spinal surgery Patients who have given pre-operative informed written consent

Exclusion criteria

Exclusion Criteria:

-

05

Study design

Observational model
Ecologic or community
Time perspective
Cross-sectional
Enrollment
80 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Group A

    Patients were aged 60-69 years

    Diagnostic Test: Cerebrospinal fluid densitometry · Diagnostic Test: blood routine examination · Diagnostic Test: Blood electrolyte examination

  • Group B

    Patients were aged 70-79 years

    Diagnostic Test: Cerebrospinal fluid densitometry · Diagnostic Test: blood routine examination · Diagnostic Test: Blood electrolyte examination

  • Group C

    Patients were aged 80-89 years

    Diagnostic Test: Cerebrospinal fluid densitometry · Diagnostic Test: blood routine examination · Diagnostic Test: Blood electrolyte examination

  • Group D

    Patient age \> 90 years

    Diagnostic Test: Cerebrospinal fluid densitometry · Diagnostic Test: blood routine examination · Diagnostic Test: Blood electrolyte examination

Interventions

  • Diagnostic testCerebrospinal fluid densitometry

    After obtaining the patient's cerebrospinal fluid specimen, the actual mass of the cerebrospinal fluid was measured by pipetting 1000 μL of cerebrospinal fluid specimen on an analytical balance using a pipette gun, and all specimens were measured three times and the average of the three times was taken as the final mass of 1000 μL of that specimen. After the mass measurement, the residual cerebrospinal fluid was disposed of as medical waste. The density of each specimen was obtained according to the density to mass conversion formula ρ=m/v.

  • Diagnostic testblood routine examination

    After obtaining the patient's blood specimens, they were sent to the laboratory for blood routine examination.

  • Diagnostic testBlood electrolyte examination

    After obtaining the patient's blood specimens, they were sent to the laboratory for blood electrolyte examination.

06

What researchers measure

Primary outcomes

  1. Cerebrospinal fluid density

    After obtaining the mass of cerebrospinal fluid, the density was calculated from ρ=m/v

    Time frame: baseline (before anesthesia)

Secondary outcomes

  1. Blood sugar

    Plasma glucose level

    Time frame: baseline (before anesthesia)

  2. Plasma K+ concentration

    Plasma K+ concentration

    Time frame: baseline (before anesthesia)

  3. Plasma Cl- concentration

    Plasma Cl- concentration

    Time frame: baseline (before anesthesia)

  4. WBC

    Leukocyte concentration in blood

    Time frame: baseline (before anesthesia)

  5. Neutrophil concentration in blood

    Neutrophil concentration in blood

    Time frame: baseline (before anesthesia)

  6. Lymphocyte concentration in blood

    Lymphocyte concentration in blood

    Time frame: baseline (before anesthesia)

  7. C-reactive protein (CRP)

    C-reactive protein concentration in plasma

    Time frame: baseline (before anesthesia)

07

Study locations

1 site
  • Zhiming Zhang
    Chenzhou, Hunan 423000, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2022; primary completion for May 2023, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 1, 2022
First posted
Dec 9, 2022
StartEst.
Dec 1, 2022
Primary completionEst.
May 31, 2023
CompletionEst.
May 31, 2023
Last update
Dec 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05644535
Lead sponsor
First People's Hospital of Chenzhou
Responsible party
zhiming zhang (MD, Ph.D, First People's Hospital of Chenzhou) — Principal investigator
First posted
Dec 9, 2022
Start date
Dec 1, 2022 (estimated)
Primary completion
May 31, 2023 (estimated)
Completion
May 31, 2023 (estimated)
Last update
Dec 9, 2022

Study contacts

Zhiming Zhang
Contact
otc0735@163.com
+8613875555649
Yuan Qin
Contact
uscqinyuan@163.com
13657381087

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion